PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go:
Expired
investment:
£312,463
WeTRAIN is a new way to have fun with personal training. They are the first shared personal training company and by doing this, they are creating a market of social exercise. WeTRAIN makes it easy for friends to have high quality, personalised training in a variety of different classes.
days to go:
Expired
investment:
£437,138
Tribal Sports Nutrition (TSN) uses the revitalising properties of the Baobab fruit to create energy smoothies. TSN claims that its smoothies are less concentrated than other sports nutrition brands, are 100% organic, and easy on the stomach. The company also incorporates vitamin C, antioxidants, fibre, and electrolytes into the smoothies to make it the on-the-go snack for active lifestyle consumers. TSN asserts that its baobab ingredient is wild-harvested by cooperatives in Africa, bringing income to people and preserving the local ecology. The company received a certification from the Organic Food Federation (OFF) and aims to achieve B Corp status. TSN's products have been listed in Sainsbury's and on Amazon. It will use the investment to double its existing product offering in 2021 and launch hydration, plant protein recovery products, and Baobab energy snacks.
days to go:
Expired
investment:
£421,647
Wireless Fitness allows fitness instructors to stream their music and voice from their phone to the phones of their class participants who listen in using their own headphones. This allows users to participate in their favourite classes without disturbing other park users or nearby local residents.
days to go:
Expired
investment:
£10,041
Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.
days to go:
Expired
investment:
£386,829
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.
days to go:
Expired
investment:
£340,928
